In this study, we found that cognitive deficits in elderly mice could be elicited by unilateral nephrectomy on postoperative day 3. Importantly, the effect of anesthesia/surgical stress was notably reversed by ononin pretreatment. Mechanically, we demonstrated that ononin could remarkably attenuate unilateral nephrectomy-induced hippocampal neuroinflammation and oxidative distress in elderly mice. As a result, our findings provide preclinical evidence that ononin may act as a promising therapeutic drug for anesthesia/surgery-triggered cognitive impairment via mitigating hippocampal inflammation and oxidative insults.
Previously, several POCD models in rodents have been established to mimic the condition that patients may suffer from cognitive impairment following surgery, including exploratory laparotomy [36], tibial fracture surgery [37], and excision of important organs under anesthesia [38]. In the current study, unilateral nephrectomy in aged mice was conducted under sevoflurane anesthesia to set up a POCD model. As demonstrated in previous reports [21, 38], we corroborated that this surgical approach could elicit early postoperative cognitive impairment in aged mice. Meanwhile, the aged mice that underwent unilateral nephrectomy did not alter mean velocity and total travel distance relative to the controls in the OFT, indicating that the cognitive deficits in surgery-treated mice were not attributed to the impairment of spontaneous locomotor ability. Also, we found that our protocol had no impact on the kidney function and mortality in aged mice after surgery (data not shown), which is consistent with the previously published literature [39] and in line with clinical practice.
The MWM is a classical approach for the evaluation of hippocampal-dependent learning and memory in rodents [31]. In this study, after 5 consecutive days of MWM training, the aged mice in each group were able to find the platform quickly and possessed similar spatial memory in the MWM before surgery. On day 3 postsurgery, mice exposed to anesthesia/surgery manifested memory deficits, as evidenced by increased latency to the previous platform and decreased percentage of time spent in the target quadrant, as well as a reduced number of crossing platforms compared to the controls. These results are in agreement with previous studies [18, 40]. Of note, pre-operative intervention with ononin significantly reversed the water-maze impairment in aged mice, denoting that ononin could ameliorate cognitive function following anesthesia/surgery.
A growing body of research has demonstrated the crucial role of neuroinflammation in the pathophysiology of POCD [41]. Liu and colleagues [17] found that suppression of hippocampal neuroinflammation by Sirtuin 3 protected elderly mice from anesthesia/surgery-induced cognitive impairment. Likewise, a large number of preclinical studies unveiled that administration of anti-neuroinflammatory drugs, such as dexmedetomidine [18], fluoxetine [42], and omega-3 fatty acids [14], could relieve surgery-triggered neuroinflammation and preserve learning and memory abilities in aged rodents. In addition, it is well-documented that microglia can exert a key role in immune regulation and phagocytosis of dangerous cells or materials [43]. Surgery-evoked elevations of hippocampal pro-inflammatory cytokines can further hyperactivate microglia and exacerbate neuroinflammation [44]. Activated microglia can elicit neurotoxicity, resulting in damage to synapses and neurons [45, 46]. Our results revealed that hippocampal levels of TNF-α, IL-1β, and IL-6 were markedly elevated on days 1 and 3 postsurgery, accompanied by overt activation of Iba1-labelled microglia, which was consistent with previous researches [12, 17]. By contrast, ononin pretreatment attenuated anesthesia/surgery-triggered increases in hippocampal proinflammatory cytokines and reversed microglial activation to some degree. Thus, the improvement of anesthesia/surgery-induced cognitive decline by ononin may be closely related to its anti-neuroinflammatory properties.
Clinical evidence has uncovered that advanced age is one of the main risk factors of developing POCD [47, 48]. As individuals age, oxidative stress in the brain becomes increasingly evident, characterized by increased ROS levels and decreased anti-oxidant enzymes SOD activity [49]. Oxidative imbalances can cause the accumulation of harmful proteins and dysfunctional mitochondria in elderly patients, which is another pivotal factor contributing to POCD [35, 50]. Crucially, oxidative distress and neuroinflammation coexist and interact, further exacerbating anesthesia/surgery-induced cognitive impairment [18, 51]. Accumulating studies have revealed that ononin possessed potent antioxidant effects [52]. For example, a recent study demonstrated that ononin treatment could mitigate cognitive impairment in AD rats elicited by aluminium chloride through suppressing oxidative distress and neuroinflammation [23]. In addition, Yan and colleagues [53] found that ononin could effectively alleviate OGD/R-evoked HT22 cell damage and apoptosis by suppressing oxidative distress. This knowledge inspired us to explore the latent benefits of ononin on oxidative insults and cognitive decline induced by anesthesia/surgery. In concordant with previous researches [16], we unveiled that unilateral nephrectomy could trigger hippocampal oxidative distress in surgery-treated mice, as evidenced by apparently reduced SOD activity and elevated MDA content on days 1 and 3 postsurgery. Not surprisingly, ononin prophylaxis appreciably reversed these changes, which was in accordance with the decreased neuroinflammation in the hippocampus. This coincides with the extensively believed antioxidant characteristics of ononin in several neurological diseases, such as AD [23]. Accordingly, these findings suggest that the neuroprotective role of ononin in POCD may be implicated in its antioxidant effects as well.
In our study, the reason why we selected the dosage of 30 mg/kg ononin and injected it intraperitoneally into aged mice 15 min before surgery was based on the safety and efficacy of ononin application. A previous study [25] showed that a representative component of isoflavones in Astragalus trimensis L. (Fabaceae), calycosin-7-O-β-D-glucoside, which is a structural analogue of ononin, administered intraperitoneally 15 min prior to cerebral ischemia could afford neuroprotective effects in a rat model of MCAO ischemia-reperfusion. Combined with the results of our pilot research (n = 6 in each group, unpublished data), ononin (30 mg/kg) administered intraperitoneally 15 min before surgery was also safe and substantially mitigated cognitive deficits in surgery-treated mice and the accumulation of hippocampal proinflammatory cytokines and MDA levels. Therefore, we finally chose the dosage of 30 mg/kg ononin for this study and injected it intraperitoneally into aged mice 15 min before surgery to further determine whether ononin could play a neuroprotective role against POCD.
It is essential to acknowledge some limitations in our study. First, we only explored the therapeutic potential of ononin in the early stage of POCD, therefore, further studies are needed to probe the role of ononin in long-term cognitive dysfunction after surgery. Second, increasing evidence has demonstrated that anesthesia and/or surgery could cause neuroinflammation and cognitive decline in elderly mice [54, 55]. Referring to many previous research designs [56, 57], we did not set up a “sham surgery” group as well because sham surgery is also a surgical trauma and requires anesthesia. In clinical practice, anesthesia and surgery are almost inseparable, so we mainly investigate the impacts of anesthesia and surgery in a group on postoperative cognitive function. Third, it is well known that there are many biological differences between humans and mice, so intraperitoneal injection of ononin (30 mg/kg) as a model in elderly mice cannot be extrapolated to humans. Fourth, although our results provide evidence that ononin may hinder or postpone the development of POCD, the precise molecular mechanisms remain poorly understood and need further investigation. Finally, to improve clinical relevance and translational value, future research is needed to determine the optimal dosage, administration methods, as well as the timing of ononin application in patients to diminish cognitive dysfunction induced by anesthesia/surgery.
In conclusion, our study demonstrated that ononin pretreatment could ameliorate anesthesia/surgery-induced cognitive deficits in elderly mice, possibly through its anti-inflammatory and antioxidant effects, which provides a valuable theoretical basis for its use in the prevention and treatment of postoperative cognitive impairment.